{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:46:23Z","timestamp":1767987983502,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Abscopal effect refers to the shrinkage or regression of metastatic tumours that are distant from the irradiated field. Radiotherapy combined with immunotherapy can increase the occurrence of the abscopal effect. This case report describes a female patient with lung metastases from hepatocellular carcinoma who exhibited shrinkage and regression of non-irradiated lung lesions following combined radiotherapy and immunotherapy. The patient is currently stable and remains on treatment and follow-up. We discuss the potential mechanisms of the abscopal effect to provide clinical evidence supporting the combined use of radiotherapy and immunotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2025-267129","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:35:19Z","timestamp":1767969319000},"page":"e267129","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Abscopal effect following combined radiotherapy and immunotherapy in pulmonary metastases"],"prefix":"10.1136","volume":"19","author":[{"given":"HuiLian","family":"Zhang","sequence":"first","affiliation":[{"name":"Nanfang Hospital, Department of Radiation Oncology, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiYi","family":"Li","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Department of Radiation Oncology, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-9255","authenticated-orcid":false,"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Department of Radiation Oncology, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YuQin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Department of Radiation Oncology, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026010906351075000_19.1.e267129.1","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234"},{"key":"2026010906351075000_19.1.e267129.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012"},{"key":"2026010906351075000_19.1.e267129.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"2026010906351075000_19.1.e267129.4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2026010906351075000_19.1.e267129.5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00511","article-title":"Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition","volume":"10","author":"Trommer","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026010906351075000_19.1.e267129.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"2026010906351075000_19.1.e267129.7","doi-asserted-by":"crossref","unstructured":"Zhang T-Q , Geng Z-J , Zuo M-X , et al . Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic arteryinfusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C(TRIPLET): a phase II study. Signal Transduct Target Ther 2023;8.","DOI":"10.1038\/s41392-023-01663-6"},{"key":"2026010906351075000_19.1.e267129.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026010906351075000_19.1.e267129.9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026010906351075000_19.1.e267129.10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(24)01772-0","article-title":"Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial","volume":"404","author":"Ponvilawan","year":"2024","journal-title":"Lancet"},{"key":"2026010906351075000_19.1.e267129.11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026010906351075000_19.1.e267129.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0793"},{"key":"2026010906351075000_19.1.e267129.13","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.3390\/ijms222011061","article-title":"The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"IJMS"},{"key":"2026010906351075000_19.1.e267129.14","article-title":"Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"key":"2026010906351075000_19.1.e267129.15","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026010906351075000_19.1.e267129.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102762","article-title":"Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade","volume":"12","author":"Zhao","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026010906351075000_19.1.e267129.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.06.001"},{"key":"2026010906351075000_19.1.e267129.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.30"},{"key":"2026010906351075000_19.1.e267129.19","unstructured":"Sun J . Efficacy and safety of super-hyperfractionation pulse radiotherapy combined with immune checkpoint inhibitor for advanced non-small cell lung cancer. clinicaltrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/study\/NCT05754203"},{"key":"2026010906351075000_19.1.e267129.20","unstructured":"Chang AR . Abscopal Effect from the Addition of Low-dose Radiotherapy in PolymetastaticCancer Patients Receiving Stereotactic Radiotherapy: a Multicenter, Single-arm ClinicalStudy (KROG 22-11) [. clinicaltrials.gov; 2024. Available: https:\/\/clinicaltrials.gov\/study\/NCT05733156"},{"key":"2026010906351075000_19.1.e267129.21","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.ijrobp.2020.07.2215","article-title":"Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients","volume":"108","author":"Li","year":"2020","journal-title":"J. Radiat. Oncol. Biol. Phys"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-267129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:35:21Z","timestamp":1767969321000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-267129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bcr-2025-267129"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-267129","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}